A practical reference on 肠促胰素: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-14. Anything still debated is marked as such rather than presented as settled.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
== Research == Dayhoff began a PhD in quantum chemistry under George Kimball in the Columbia University Department of Chemistry. In her graduate thesis, Dayhoff pioneered the use of computer capabilities – i.e. mass-data processing – to theoretical chemistry; specifically, she devised a method of applying punched-card business machines to calculate the resonance energies of several polycyclic organic molecules. Her management of her research data was so impressive that she was awarded a Watson Computing Laboratory Fellowship. As part of this award, she received access to "cutting-edge IBM electronic data processing equipment" at the lab.
is the liquid-air surface tension (force/unit length), θ is the contact angle, ρ is the density of liquid (mass/volume), g is the local acceleration due to gravity (length/square of time), and r is the radius of tube. As r is in the denominator, the thinner the space in which the liquid can travel, the further up it goes. Likewise, lighter liquid and lower gravity increase the height of the column. For a water-filled glass tube in air at standard laboratory conditions, γ = 0.0728 N/m at 20 °C, ρ = 1000 kg/m3, and g = 9.81 m/s2. Because water spreads on clean glass, the effective equilibrium contact angle is approximately zero. For these values, the height of the water column is
Structurally, relaxin is a heterodimer of two peptide chains of 24 and 29 amino acids linked by three disulfide bridges, and it appears related to insulin. Relaxin is produced from its prohormone, "prorelaxin", by post-translational proteolytic cleavage of its signal peptide and C domain peptide.
Simple compounds that are converted into other compounds with the assistance of cofactors. For example, the synthesis of phospholipids requires acetyl CoA, while the synthesis of another membrane component, sphingolipids, requires NADH and FADH for the formation the sphingosine backbone. The general equation for these examples is:
Like Canada hemlock, this tree suffers severely from the hemlock woolly adelgid. Several species of pines characteristic of the Appalachians are eastern white pine (Pinus strobus ), Virginia pine (Pinus virginiana), pitch pine (Pinus rigida ), Table Mountain pine (Pinus pungens) and shortleaf pine (Pinus echinata). Red pine (Pinus resinosa) is a boreal species that forms a few high elevation outliers as far south as West Virginia. All of these species except white pine tend to occupy sandy, rocky, poor soil sites, which are mostly acidic in character. White pine, a large species valued for its timber, tends to do best in rich, moist soil, either acidic or alkaline in character. Pitch pine is also at home in acidic, boggy soil, and Table Mountain pine may occasionally be found in this habitat as well. Shortleaf pine is generally found in warmer habitats and at lower elevations than the other species. All the species listed do best in open or lightly shaded habitats, although white pine also thrives in shady coves, valleys, and on floodplains. The Appalachians are characterized by a wealth of large, beautiful deciduous broadleaf (hardwood) trees. Their occurrences are best summarized and described in E. Lucy Braun's 1950 classic, Deciduous Forests of Eastern North America (Macmillan, New York).
Sources: en.wikipedia.org
=== Etymology === Lactobacillic acid and Lactobacillussäure are translations of the English term 'lactobacillic acid', which scientists proposed when this fatty acid was discovered (1950) in a Lactobacillus species. In the German-language literature, the term lactobacillic acid is used more frequently than lactobacillus acid. As early as 1938, another group of researchers discovered an unusual fatty acid from the bacterium Agrobacterium tumefaciens (at that time called Bacterium tumefaciens or Phytomonas tumefaciens) was isolated and after the generic name as phytomonic acid. According to the knowledge of scientists at the time, this saturated fatty acid had the molecular formula C20H40O2. The proposed structure was a branched-chain fatty acid with a methyl group as a branch, methylnonadecanoic acid. However, K. Homann et al. were able to show in 1955 that this compound isolated from P. tumefaciens was in fact lactobacillic acid. According to them, the substance originally investigated had been contaminated.
Zipline originated from Romotive, a company founded in 2011 by Keller Rinaudo Cliffton that produced an iPhone-controlled robot. Romotive ceased operations in 2014, after which Rinaudo, Ryan Oksenhorn, William Hetzler, and Keenan Wyrobek began developing a fixed-wing drone platform intended for medical delivery. This effort became the basis for Zipline. The company began operations in Rwanda in October 2016 following a government agreement to deliver blood and medical supplies to rural clinics from a centralized distribution center. A second Rwandan center opened in 2018 as the scope of deliveries expanded to include routine vaccines and essential medicines. Zipline launched operations in Ghana on April 24, 2019 under a government contract that provided drone delivery services to public-sector health facilities. The program later expanded to multiple distribution centers serving additional regions. Beginning in 2020, the company participated in regulatory programs, including the FAA type-certification process for delivery drones in the United States. It also deployed temperature-controlled payload systems to support delivery of vaccines requiring cold-chain conditions, including during COVID-19 vaccination campaigns in parts of Africa. From 2022 onward, Zipline initiated operations outside Africa, including a partner-operated distribution center in Japan and limited pilot projects in the United States. It also introduced a new platform aimed at home deliveries in denser urban and suburban environments.
Henry Slattery (born 22 January 1986) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). Henry Slattery attended Rostrevor College in Adelaide, South Australia. Slattery was recruited by Essendon with selection 46 in the 2004 AFL draft. He had previously played for West Adelaide in the SANFL. He made his debut in 2005 against St Kilda, kicking a goal in what was Matthew Lloyd's 200th AFL game. His first three seasons were limited by hip and knee injuries before he cemented his place in the Essendon starting team, often as a small, lock-down defender or defensive midfielder. At the end of the 2012 AFL season, Slattery decided to leave Essendon in search of greater opportunities at AFL level, after playing in only 2 games for the year, nominating South Australia as his preferred destination. He was not selected in the 2012 AFL draft, but was recruited by the Port Adelaide Magpies in the South Australian National Football League (SANFL). Slattery, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his team-mates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency.
=== Evaluating similarity === Often the purpose of seeking a structural superposition is not so much the superposition itself, but an evaluation of the similarity of two structures or a confidence in a remote alignment. A subtle but important distinction from maximal structural superposition is the conversion of an alignment to a meaningful similarity score. Most methods output some sort of "score" indicating the quality of the superposition. However, what one actually wants is not merely an estimated "Z-score" or an estimated E-value of seeing the observed superposition by chance but instead one desires that the estimated E-value is tightly correlated to the true E-value. Critically, even if a method's estimated E-value is precisely correct on average, if it lacks a low standard deviation on its estimated value generation process, then the rank ordering of the relative similarities of a query protein to a comparison set will rarely agree with the "true" ordering. Different methods will superimpose different numbers of residues because they use different quality assurances and different definitions of "overlap"; some only include residues meeting multiple local and global superposition criteria and others are more greedy, flexible, and promiscuous. A greater number of atoms superposed can mean more similarity but it may not always produce the best E-value quantifying the unlikeliness of the superposition and thus not as useful for assessing similarity, especially in remote homologs.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。